{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:10:44Z","timestamp":1785546644284,"version":"3.56.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.nmd.2026.106360","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:10:08Z","timestamp":1769616608000},"page":"106360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Clinically important improvements in 6-minute walk distance and forced vital capacity in adults with late-onset Pompe disease switching from alglucosidase alfa to cipaglucosidase alfa plus miglustat in the PROPEL study"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-3642","authenticated-orcid":false,"given":"Stephan","family":"Wenninger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Kushlaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Hummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Gloeckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Holdbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Peceny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristl G.","family":"Claeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2026.106360_bib0001","first-page":"1","article-title":"Pompe disease: clinical perspectives","volume":"7","author":"Cabello","year":"2017","journal-title":"Orphan Drugs"},{"key":"10.1016\/j.nmd.2026.106360_bib0002","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2026.106360_bib0003","doi-asserted-by":"crossref","first-page":"291","DOI":"10.21037\/atm.2019.04.15","article-title":"Challenges in treating Pompe disease: an industry perspective","volume":"7","author":"Do","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.nmd.2026.106360_bib0004","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2026.106360_bib0005","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","article-title":"Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study","volume":"89","author":"Kuperus","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2026.106360_bib0006","doi-asserted-by":"crossref","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2026.106360_bib0007","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1007\/s00415-021-10409-9","article-title":"STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa","volume":"268","author":"Gutschmidt","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2026.106360_bib0008","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jimd.12272","article-title":"Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: prospective analysis from the French Pompe Registry","volume":"43","author":"Semplicini","year":"2020","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nmd.2026.106360_bib0009","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125358","article-title":"Improved efficacy of a next-generation ERT in murine Pompe disease","volume":"4","author":"Xu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.nmd.2026.106360_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1451512","article-title":"Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease","volume":"15","author":"Byrne","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2026.106360_bib0011","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1007\/s00415-024-12236-0","article-title":"104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)","volume":"271","author":"Schoser","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2026.106360_bib0012","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"Schoser","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2026.106360_bib0013","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2026.106360_bib0014","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13023-024-03156-3","article-title":"Minimal clinically important differences in six-minute walking distance in late-onset Pompe disease","volume":"19","author":"Claeys","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2026.106360_bib0015","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13023-017-0633-1","article-title":"Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome","volume":"12","author":"Schrover","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2026.106360_bib0016","first-page":"21","article-title":"The minimal clinically important difference and its use in neuromuscular disorder","volume":"24","author":"Uysal","year":"2025","journal-title":"Pract Neurol (US)"},{"key":"10.1016\/j.nmd.2026.106360_bib0017","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.jval.2023.03.2304","article-title":"CO168 Defining clinically meaningful thresholds (CMT) for forced vital capacity (FVC) and six-minute walk test (6MWT) in patients with late-onset Pompe disease (LOPD)","volume":"26","author":"Berger","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.nmd.2026.106360_bib0018","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16223","article-title":"Establishing how much improvement in lung function and distance walked is clinically important for adult patients with Pompe disease","volume":"31","author":"Lika","year":"2024","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2026.106360_bib0019","first-page":"523","article-title":"Defining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: lessons learned from the COMET study in Pompe disease","volume":"12","author":"Berger","year":"2025","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2026.106360_bib0020","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/mus.28420","article-title":"Switching enzyme replacement therapy for late-onset Pompe disease from alglucosidase Alfa to cipaglucosidase Alfa plus Miglustat: post hoc effect size analysis of PROPEL","volume":"72","author":"Kushlaf","year":"2025","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2026.106360_bib0021","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s41687-024-00805-w","article-title":"Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease","volume":"8","author":"Kishnani","year":"2024","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.nmd.2026.106360_bib0022","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13023-023-02974-1","article-title":"Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease","volume":"19","author":"Boentert","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2026.106360_bib0023","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jama.2014.13128","article-title":"Minimal clinically important difference: defining what really matters to patients","volume":"312","author":"McGlothlin","year":"2014","journal-title":"JAMA"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626000283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626000283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:36:34Z","timestamp":1773704194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896626000283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":23,"alternative-id":["S0960896626000283"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2026.106360","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinically important improvements in 6-minute walk distance and forced vital capacity in adults with late-onset Pompe disease switching from alglucosidase alfa to cipaglucosidase alfa plus miglustat in the PROPEL study","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2026.106360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106360"}}